- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02347384
Project JAY THA Registration Study
A Prospective, Randomized, Multicenter Clinical Study in Chinese Subjects to Compare the Safety and Efficacy of the Delta PLUS Femoral Head and SL-TWIN Stem With BIOLOX Forte Ball Head and SL-PLUS Stem in Total Hip Arthroplasty
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As the incidence of joint disease continues to increase, an ever growing percentage of the affected population will undergo total hip arthroplasty (THA). This recent upward trend for THA procedures appears to be directly related to the prevalence of certain health factors. Specifically, longer life spans, rising obesity rates, and increasing physical activity levels in relatively younger populations are all examples of factors that may significantly contribute to hip degeneration. While strategies such as weight reduction, lifestyle change, or drug therapy may offer temporary relief from the symptoms of joint degeneration, THA remains the standard of care for subjects experiencing significant losses in quality of life due to advanced hip disease.
There has been an increase in imported hip prostheses during the past decade, so that surgeons now have more choices of implants. However, the high cost of imported prostheses has become a barrier to the development of hip replacement in China and caused many patients requiring immediate hip replacement to have to delay or miss their surgery. The development and promotion of high-quality domestic joint implants and surgical instruments is the key to the development of joint replacement technique in China.
The primary objective of this study is to demonstrate non-inferiority of subjects implanted with the Delta PLUS Femoral Head + SL-TWIN Stem compared to a randomized concurrent control group of subjects implanted with the BIOLOX forte ball head + SL-PLUS Stem in terms of mean Harris Hip Score (HHS) at 1 year.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Henan
-
Luoyang, Henan, China, 471002
- Luoyang Orthopedic-Traumatological Hospital
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China, 014010
- Inner Mongolia Bao Gang Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- The First Teaching Hospital of Xinjiang Medical University
-
Ürümqi, Xinjiang, China, 830099
- Traditional Chinese Medicine hospital of Xinjiang Uygur Autonomous Region
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, aged between 50 and 75 years inclusive of Chinese ethnicity.
- Subject presents with osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, avascular necrosis of hip joint, developmental dysplasia of the hip, or femoral neck fracture requiring primary total hip replacement.
- Subject who is able to give voluntary, written informed consent to participate in the study and from whom consent has been obtained by signing and dating an EC-approved consent form.
- Subject who is able to understand this clinical study, co-operates with the investigational procedures and is willing to return to the hospital for all the required post-operative follow-ups for up to 12 months.
- Life expectancy of subject is over 2 years.
Exclusion Criteria:
- Bilateral hip disease with the anticipated need for bilateral hip implant during study participation (i.e., within the next 12 months).
- Subject experienced prior joint replacement surgery on any major joint (hip, knee) in lower limb within the last 12 months.
- Subject with developmental dysplasia of the hip of CROWE grade 3 or 4.
- Subject has known or suspected metal sensitivity.
- Subject is known to have insufficient bone stock resulting from conditions such as cancer, significant osteoporosis or metabolic bone disorders, which cannot provide adequate support and/or fixation to the prosthesis.
- Subject is severely obese (BMI>35).
- Subject had an active infection or sepsis (treated or untreated).
- Subject has conditions that may compromise implant stability or postoperative recovery (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency, hip abduction muscle strength less than grade IV or complete loss, or neuromuscular disease).
- Subject has an emotional or neurological condition that would affect their ability or willingness to participate in the study (e.g. cognitive disorder, mental illness, mental retardation).
- Subject is immunosuppressed, has an autoimmune disorder, or an immunosuppressive disorder. For examples, subject is on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses) or has acquired immunodeficiency syndrome (AIDS).
- Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits.
- Subject was enrolled in another investigational drug, biologic, or device study in the last 12 months.
- Subject is a woman who is pregnant or lactating,or intends to become pregnant during the course of the study.
- Known alcohol and/or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Delta PLUS Femoral Head + SL-TWIN Stem
Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
|
Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
|
Active Comparator: BIOLOX forte ball head + SL-PLUS Stem
Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
|
Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Harris Hip Score
Time Frame: 1 year post-operative
|
1 year post-operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Clinical Success, as indicated by A) No revision of any device component; and B) Total Harris Hip Score greater than or equal to 80 (excellent to good score); and C) Radiologic success.
Time Frame: 1 year post-operative
|
A successful individual outcome for a subject in total hip arthroplasty will be characterized at 1 year postoperative by a composite of three success criteria: A. No revision of any device component; and B. Total Harris Hip Score greater than or equal to 80 (excellent to good score); and C. Radiologic success. |
1 year post-operative
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SF-12 Health Survey
Time Frame: 1 year post-operative
|
1 year post-operative
|
Number of adverse events
Time Frame: Up to 1 year post-operative
|
Up to 1 year post-operative
|
The Western Ontario and McMaster Universities Arthritis Index(WOMAC)
Time Frame: 1 year post-operative
|
1 year post-operative
|
Collaborators and Investigators
Investigators
- Study Chair: Li Cao, First Affiliated Hospital of Xinjiang Medical University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Fractures, Bone
- Wounds and Injuries
- Leg Injuries
- Congenital Abnormalities
- Joint Diseases
- Musculoskeletal Diseases
- Femoral Fractures
- Hip Injuries
- Musculoskeletal Abnormalities
- Joint Dislocations
- Hip Fractures
- Hip Dislocation
- Arthritis
- Necrosis
- Developmental Dysplasia of the Hip
- Hip Dislocation, Congenital
- Femoral Neck Fractures
Other Study ID Numbers
- 14-4560-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Delta PLUS Femoral Head + SL-TWIN Stem
-
Smith & Nephew Orthopaedics (Beijing) LimitedCompleted
-
Limacorporate S.p.aActive, not recruiting
-
Smith & Nephew Orthopaedics AGCompleted
-
Kantonsspital Baselland BruderholzSmith & Nephew, Inc.Completed
-
Zimmer BiometRecruitingHip Pain Chronic | Hip Fractures | Hip Injuries | Hip Disease | Hip ArthritisUnited States
-
DePuy OrthopaedicsCompleted
-
Stockholm South General HospitalKarolinska InstitutetUnknown
-
Federal State Budgetary Organization, Federal Center...CompletedOsteoarthritis, Hip | Degenerative Osteoarthritis | Rheumatic ArthritisRussian Federation
-
Zimmer BiometActive, not recruitingPain | Arthritis | OsteoarthrosisSweden, Finland, Denmark
-
National Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1United States, Canada, Australia, New Zealand, Puerto Rico